FR2814642B1 - Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee - Google Patents

Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee

Info

Publication number
FR2814642B1
FR2814642B1 FR0012570A FR0012570A FR2814642B1 FR 2814642 B1 FR2814642 B1 FR 2814642B1 FR 0012570 A FR0012570 A FR 0012570A FR 0012570 A FR0012570 A FR 0012570A FR 2814642 B1 FR2814642 B1 FR 2814642B1
Authority
FR
France
Prior art keywords
organism
interest
recombinase
transgenic mouse
targeted recombination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0012570A
Other languages
English (en)
Other versions
FR2814642A1 (fr
Inventor
Pierre Chambon
Daniel Metzger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ASS POUR LE DEV de la RECH EN
Original Assignee
ASS POUR LE DEV de la RECH EN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ASS POUR LE DEV de la RECH EN filed Critical ASS POUR LE DEV de la RECH EN
Priority to FR0012570A priority Critical patent/FR2814642B1/fr
Priority to US09/853,033 priority patent/US7112715B2/en
Priority to AT06101289T priority patent/ATE398922T1/de
Priority to EP01986247A priority patent/EP1322152A2/fr
Priority to DE60134588T priority patent/DE60134588D1/de
Priority to EP06101289A priority patent/EP1692936B1/fr
Priority to PCT/IB2001/002246 priority patent/WO2002028175A2/fr
Publication of FR2814642A1 publication Critical patent/FR2814642A1/fr
Application granted granted Critical
Publication of FR2814642B1 publication Critical patent/FR2814642B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4741—Keratin; Cytokeratin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • A01K2217/203—Animal model comprising inducible/conditional expression system, e.g. hormones, tet
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C07K2319/715—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16 containing a domain for ligand dependent transcriptional activation, e.g. containing a steroid receptor domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Environmental Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FR0012570A 2000-10-03 2000-10-03 Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee Expired - Fee Related FR2814642B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR0012570A FR2814642B1 (fr) 2000-10-03 2000-10-03 Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
US09/853,033 US7112715B2 (en) 2000-10-03 2001-05-11 Transgenic mouse for targeted recombination mediated by modified Cre-ER
EP01986247A EP1322152A2 (fr) 2000-10-03 2001-09-28 Sousris transgenique pour recombinaison ciblee a mediation par cre-er modifie
DE60134588T DE60134588D1 (de) 2000-10-03 2001-09-28 Verwendung des Cre-ERT2 Fusionsproteins zur konditionalen gezielten DNS-Rekombination in der Maus
AT06101289T ATE398922T1 (de) 2000-10-03 2001-09-28 Verwendung des cre-ert2 fusionsproteins zur konditionalen gezielten dns-rekombination in der maus
EP06101289A EP1692936B1 (fr) 2000-10-03 2001-09-28 Méthode utilisant la protéine de fusion Cre-ERT2 pour la recombinaison dirigée conditionnelle de l'ADN chez la souris
PCT/IB2001/002246 WO2002028175A2 (fr) 2000-10-03 2001-09-28 Sousris transgenique pour recombinaison ciblee a mediation par cre-er modifie

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0012570A FR2814642B1 (fr) 2000-10-03 2000-10-03 Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee

Publications (2)

Publication Number Publication Date
FR2814642A1 FR2814642A1 (fr) 2002-04-05
FR2814642B1 true FR2814642B1 (fr) 2005-07-01

Family

ID=8854918

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0012570A Expired - Fee Related FR2814642B1 (fr) 2000-10-03 2000-10-03 Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee

Country Status (5)

Country Link
US (1) US7112715B2 (fr)
EP (1) EP1692936B1 (fr)
AT (1) ATE398922T1 (fr)
DE (1) DE60134588D1 (fr)
FR (1) FR2814642B1 (fr)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2485939C (fr) * 2002-05-29 2013-10-29 Regeneron Pharmaceuticals, Inc. Systeme d'expression eucaryote inductible
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
US20080307537A1 (en) * 2005-03-31 2008-12-11 Dana-Farber Cancer Institute, Inc. Compositions and Methods for the Identification, Assessment, Prevention, and Therapy of Neurological Diseases, Disorders and Conditions
US20090307784A1 (en) * 2005-10-21 2009-12-10 Medical Research Council Methods of Analysing Cell Behaviour
WO2007095278A2 (fr) * 2006-02-15 2007-08-23 The Regents Of The University Of Michigan Criblage de réseaux pour trouver des antagonistes et analyses de l'hyperthrophie cardiaque
EP1942192A1 (fr) * 2007-01-08 2008-07-09 Heinrich-Pette-Institut für experimentelle Virologie und Immunologie Utilisation de la récombinase sur mesure dans le traitement des infection retrovirales
US8173792B2 (en) 2007-02-09 2012-05-08 The Board Of Trustees Of The Leland Stanford Junior University Method for regulating protein function in cells using synthetic small molecules
BRPI0807952A2 (pt) * 2007-02-20 2014-06-10 Anaptysbio Inc Sistemas de hipermutação somática
US20090165150A1 (en) * 2007-12-21 2009-06-25 Yinghui Zhou Directed complementation with removable gene of interest
US8530636B2 (en) 2008-05-07 2013-09-10 The Board Of Trustees Of The Leland Stanford Junior University Method for regulating protein function in cells in vivo using synthetic small molecules
CA2749789A1 (fr) 2009-01-22 2010-07-29 Daniel Metzger Procede pour controler temporairement l'activite biologique de proteines chez les vertebres, et ses applications
CA2757178C (fr) 2009-04-03 2020-05-19 Medical Research Council Mutants de cytidine desaminase induite par activation (aid) et procedes d'utilisation
JP2013509422A (ja) 2009-10-30 2013-03-14 シーエヌエス セラピューティクス，インク． 改良されたニュールツリン分子
WO2011057254A2 (fr) 2009-11-09 2011-05-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vaccins à base de vecteur adénoviral simien
US20130164271A1 (en) * 2010-05-27 2013-06-27 Max-Planck-Gesellschaft Zur Foederug Der Wissensch E.V. Tailored recombinase for recombining asymmetric target sites in a plurality of retrovirus strains
KR20130097156A (ko) 2010-07-26 2013-09-02 트리아니, 인코포레이티드 트랜스제닉 동물 및 이의 사용 방법
WO2012021730A2 (fr) 2010-08-11 2012-02-16 Genvec, Inc. Vaccin contre le virus syncytial respiratoire (vsr)
WO2012083297A2 (fr) 2010-12-17 2012-06-21 Genvec, Inc. Vecteurs adénoviraux avec régions d'hexon modifiées
WO2012088041A1 (fr) 2010-12-20 2012-06-28 Genvec, Inc. Vaccin contre la dengue à base d'un vecteur adénoviral
EP2764011B1 (fr) 2011-10-05 2021-04-07 GenVec, Inc. Vaccin contre le virus respiratoire syncytial à base d'un vecteur adénoviral
US20150157700A1 (en) 2012-02-02 2015-06-11 GanVec, Inc. Adenoviral vector-based malaria vaccine
KR20140123571A (ko) 2012-02-16 2014-10-22 에이티와이알 파마, 인코포레이티드 자가면역 및 염증성 질환의 치료를 위한 히스티딜­ｔｒｎａ 신테타제
WO2013130393A1 (fr) 2012-02-28 2013-09-06 Cornell University Expression persistante dirigée contre aav d'un gène d'anticorps anti-nicotine pour l'abandon du tabac
RU2766608C2 (ru) 2012-04-11 2022-03-15 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
US9676824B2 (en) 2012-05-29 2017-06-13 Genvec, Inc. Herpes simplex virus vaccine
AU2013352067A1 (en) 2012-11-28 2015-06-04 Abwiz Bio, Inc. Preparation of gene-specific templates for the use in single primer amplification
US9510569B2 (en) 2013-03-13 2016-12-06 Regeneron Pharmaceuticals, Inc. Genetically modified mouse with an inducible Acvr1 gene with a mutant R206H exon 5 that has ectopic bone formation
AU2014259719B2 (en) 2013-05-02 2019-10-03 Anaptysbio, Inc. Antibodies directed against programmed death-1 (PD-1)
US20160355573A1 (en) 2013-09-05 2016-12-08 Cornell University Gene therapy for alzheimer's and other neurodegenerative diseases and conditions
US10087224B2 (en) 2013-11-01 2018-10-02 Cornell University Gene therapy for Alzheimer's and other neurodegenerative diseases and conditions
RU2019118984A (ru) 2014-01-10 2019-08-06 Анаптисбайо, Инк. Антитела, направленные против интерлейкина-33 (il-33)
US10106583B2 (en) 2014-03-07 2018-10-23 Cornell University Materials and methods for producing cleaved, HIV-1 envelope glycoprotein trimers
KR102668549B1 (ko) 2014-06-02 2024-05-22 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Cd19를 표적화하는 키메라 항원 수용체
EP2993229A1 (fr) 2014-09-02 2016-03-09 Heinrich-Pette-Institut Leibniz-Institut für experimentelle Virologie-Stiftung bürgerlichen Rechts - Recombinase bien toléré et très spécifique mise au point sur mesure pour recombiner des sites asymétriques voulus dans une pluralité de souches de rétrovirus
US10683552B2 (en) 2014-11-25 2020-06-16 Presidents And Fellows Of Harvard College Clonal haematopoiesis
US11168369B2 (en) 2014-11-25 2021-11-09 The Brigham And Women's Hospital, Inc. Method of identifying and treating a person having a predisposition to or afflicted with a cardiometabolic disease
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
US10946094B2 (en) 2015-02-24 2021-03-16 Cornell University Adenoassociated viral mediated persistant anti-VEGF therapy for ovarian cancer
MA41867A (fr) 2015-04-01 2018-02-06 Anaptysbio Inc Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)
CA2982213C (fr) 2015-04-09 2022-10-18 Cornell University Therapie genique pour prevenir les reactions a des allergenes
CA2982555A1 (fr) 2015-04-15 2016-10-20 Anaptysbio, Inc. Anticorps diriges contre le recepteur de l'interleukine 36 (il-36r)
JP6805174B2 (ja) 2015-05-12 2020-12-23 アメリカ合衆国 神経成長因子シグナルペプチド及び副甲状腺ホルモンを含むａａｖ分離株及び融合タンパク質
IL283475B1 (en) 2015-05-28 2024-03-01 Univ Cornell Administering esterase C.1 using adenovirus as a treatment for vascular edema
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
EP3534950A4 (fr) 2016-11-01 2020-05-06 AnaptysBio, Inc. Anticorps dirigés contre la mort programmée 1 (pd -1)
KR20190098741A (ko) 2016-11-01 2019-08-22 아납티스바이오, 아이엔씨. T 세포 면역글로불린 및 뮤신 단백질 3(tim-3)에 대한 항체
WO2018129553A1 (fr) 2017-01-09 2018-07-12 Tesaro, Inc. Méthodes de traitement du cancer au moyen d'anticorps anti-tim-3
PT3565844T (pt) 2017-01-09 2023-05-02 Tesaro Inc Métodos de tratamento de cancro com anticorpos anti-pd-1
JP2020517638A (ja) 2017-04-20 2020-06-18 エータイアー ファーマ， インコーポレイテッド 肺の炎症を治療するための組成物および方法
MX2019014960A (es) 2017-06-12 2020-08-06 Obsidian Therapeutics Inc Composiciones de fosfodiesterasa de tipo 5 (pde5) y métodos de inmunoterapia.
HRP20220615T1 (hr) 2017-06-30 2022-06-24 Inscripta, Inc. Postupci, moduli, instrumenti i sustavi za automatiziranu obradu stanica
US10869465B2 (en) * 2017-08-10 2020-12-22 Osaka University Transgenic mouse model of retinal vascular disease, method of making, and method of using
US10738327B2 (en) 2017-08-28 2020-08-11 Inscripta, Inc. Electroporation cuvettes for automation
CA3074927A1 (fr) 2017-09-30 2019-04-04 Inscripta, Inc. Instrumentation d'electroporation a flux continu
WO2019133818A1 (fr) 2017-12-29 2019-07-04 Cornell University Thérapie génique pour les maladies éosinophiliques
CN112204131A (zh) 2018-03-29 2021-01-08 因思科瑞普特公司 用于诱导和转化的细胞生长速率的自动化控制
US10376889B1 (en) 2018-04-13 2019-08-13 Inscripta, Inc. Automated cell processing instruments comprising reagent cartridges
US10858761B2 (en) 2018-04-24 2020-12-08 Inscripta, Inc. Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells
US10557216B2 (en) 2018-04-24 2020-02-11 Inscripta, Inc. Automated instrumentation for production of T-cell receptor peptide libraries
WO2019209926A1 (fr) 2018-04-24 2019-10-31 Inscripta, Inc. Instrumentation automatisée pour la production de bibliothèques de peptides
US11821009B2 (en) 2018-05-15 2023-11-21 Cornell University Genetic modification of the AAV capsid resulting in altered tropism and enhanced vector delivery
CA3099441A1 (fr) 2018-06-13 2019-12-19 Regeneron Pharmaceuticals, Inc. Modele de rongeur a fibrodysplasie ossifiante progressive
KR20210052450A (ko) 2018-07-31 2021-05-10 코넬 유니버시티 기관 기능을 제어하기 위한 유전자 요법 방법
US11142740B2 (en) 2018-08-14 2021-10-12 Inscripta, Inc. Detection of nuclease edited sequences in automated modules and instruments
US10532324B1 (en) 2018-08-14 2020-01-14 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
IL292273B2 (en) 2018-08-14 2023-10-01 Inscripta Inc Devices, modules and methods for improved detection of edited sequences in living cells
EP3844263A4 (fr) 2018-08-30 2022-05-25 Inscripta, Inc. Détection améliorée de séquences à édition par nucléase dans des modules automatisés et des instruments
US20220089600A1 (en) 2018-11-22 2022-03-24 Fundació Institut De Recerca Biomèdica (Irb Barcelona) TGFß INHIBITOR AND PRODRUGS
CN114375198A (zh) 2019-05-16 2022-04-19 波士顿大学董事会 受调控的合成基因表达系统
EP3980460A2 (fr) 2019-06-05 2022-04-13 AnaptysBio, Inc. Agoniste pd-1 et son procédé d'utilisation
WO2020247815A1 (fr) * 2019-06-06 2020-12-10 Cornell University Modèle de rongeur transgénique pour la fibrose pulmonaire et ses utilisations
CN114008070A (zh) 2019-06-21 2022-02-01 因思科瑞普特公司 导致大肠杆菌赖氨酸产量增加的全基因组合理设计的突变
US10927385B2 (en) 2019-06-25 2021-02-23 Inscripta, Inc. Increased nucleic-acid guided cell editing in yeast
KR20220025839A (ko) 2019-07-01 2022-03-03 트리아니, 인코포레이티드 유전자이식 포유동물 및 이의 사용 방법
AU2020299569A1 (en) 2019-07-01 2022-01-20 Trianni, Inc. Transgenic mammals and methods of use
WO2021022208A1 (fr) 2019-08-01 2021-02-04 Kaplitt Michael G Thérapie génique ciblée pour traiter des maladies neurologiques
CN114651003A (zh) 2019-09-10 2022-06-21 黑曜石疗法公司 用于可调调节的ca2-il15融合蛋白
US20230313223A1 (en) 2019-10-15 2023-10-05 Cornell University Methods for modulating level of expression from gene therapy expression cassette
AU2020367437A1 (en) 2019-10-16 2022-06-02 Cornell University Gene therapy for Alzheimer's disease
EP4055049A1 (fr) 2019-11-05 2022-09-14 Janssen Biotech, Inc. Thérapie du myélome multiple basée sur des cellules car-t ciblées par bcma
US10689669B1 (en) 2020-01-11 2020-06-23 Inscripta, Inc. Automated multi-module cell processing methods, instruments, and systems
CN115175939A (zh) 2020-01-21 2022-10-11 博尔特生物治疗药物有限公司 抗pd-l1抗体
WO2021150701A1 (fr) 2020-01-21 2021-07-29 Bolt Biotherapeutics, Inc. Anticorps anti-pd-l1
US20210332388A1 (en) 2020-04-24 2021-10-28 Inscripta, Inc. Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells
JP2023524092A (ja) 2020-05-01 2023-06-08 ボルト バイオセラピューティクス、インコーポレーテッド 抗デクチン－２抗体
CN111705080A (zh) * 2020-05-14 2020-09-25 广州市第八人民医院 Hbv非人动物模型的构建方法及其应用
US11787841B2 (en) 2020-05-19 2023-10-17 Inscripta, Inc. Rationally-designed mutations to the thrA gene for enhanced lysine production in E. coli
CA3186601A1 (fr) 2020-07-30 2022-02-03 Anaptysbio, Inc. Therapie contre l'ichtyose a anti-recepteur de l'interleukine 36 (il-36r)
WO2022026829A1 (fr) 2020-07-30 2022-02-03 Anaptysbio, Inc. Thérapie anti-récepteur de l'interleukine 36 (il-36r) pour traiter la toxicité cutanée
MX2023004633A (es) 2020-10-23 2023-05-12 Anaptysbio Inc Moduladores del atenuador de linfocitos b y t (btla) y metodo de uso de los mismos.
WO2022116086A1 (fr) 2020-12-03 2022-06-09 Janssen Biotech, Inc. Thérapie du myélome multiple basée sur des cellules car-t ciblées par bcma
CN117440753A (zh) 2021-05-05 2024-01-23 特里安尼公司 表达嵌合马科动物-啮齿动物抗体的转基因啮齿动物及其使用方法
AU2022381186A1 (en) 2021-11-04 2024-05-16 Janssen Biotech, Inc. Bcma-targeted car-t cell therapy for multiple myeloma
WO2023077343A1 (fr) 2021-11-04 2023-05-11 Janssen Biotech, Inc. Thérapie du myélome multiple basée sur des cellules car-t ciblées par bcma
AU2022386319A1 (en) 2021-11-10 2024-05-23 Trianni, Inc. Transgenic mammals and methods of use thereof
WO2023137460A1 (fr) 2022-01-14 2023-07-20 Saccharo, Inc. Agent de liaison à l'acide polysialique dé-n-acétylé (dpsa) et son procédé d'utilisation
WO2023164727A1 (fr) 2022-02-28 2023-08-31 University Of Iowa Research Foundation Anticorps anti-a-fabp pour le diagnostic et le traitement de maladies associées à l'obésité
WO2023164695A2 (fr) 2022-02-28 2023-08-31 Janssen Biotech, Inc. Thérapie du myélome multiple basée sur des cellules car-t ciblées par bcma
WO2023212611A1 (fr) 2022-04-27 2023-11-02 Anaptysbio, Inc. Modulateurs d'atténuateur de lymphocytes b et t (btla) et leur méthode d'utilisation
WO2023239609A1 (fr) 2022-06-06 2023-12-14 Cornell University Promotion de l'absorption de nutriments par le colon
WO2024102760A2 (fr) 2022-11-07 2024-05-16 Anaptysbio, Inc. Agents de liaison à cd122 et leur procédé d'utilisation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006104A1 (fr) 1990-09-28 1992-04-16 The Dana-Farber Cancer Institute Sequences d'adn specifiques aux adipocytes et leur utilisation dans la production d'animaux transgeniques presentant un metabolisme des graisses modifie
US5917122A (en) 1992-08-26 1999-06-29 Byrne; Guerard Tetracycline repressor-mediated binary regulation system for control of gene expression in transgenic mice
JPH08504104A (ja) * 1993-05-18 1996-05-07 アンスティテュー・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル レチノイン酸レセプター蛋白をコード化する遺伝子における改変を含む遺伝子工学的マウス
US5866755A (en) 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
EP0632054A1 (fr) * 1993-06-28 1995-01-04 European Molecular Biology Laboratory Régulation de la recombinaison à site spécifique par des protéines de fusion de recombinase à site spécifique/récepteur nucléaire
WO1995017500A1 (fr) 1993-12-23 1995-06-29 Abs Global, Inc. Cellules souches d'embryons utilisees comme donneuses de noyaux et procedes de transfert de noyaux pour la production d'animaux chimeriques et transgeniques
FR2723315B1 (fr) 1994-08-02 1996-10-25 Cird Galderma Procede et composition pour stimuler la differenciation des cellules preadipocytaires et traitements therapeutiques associes
WO1996022360A1 (fr) 1995-01-20 1996-07-25 Human Genome Sciences, Inc. Reductase specifique de la prostate chez l'homme
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9517779D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
DE69631541T2 (de) 1995-09-18 2004-12-23 Ligand Pharmaceuticals, Inc., San Diego Behandlung von NIDDM (nicht-insulinabhängigem Diabetes Mellitus)
FR2745008A1 (fr) * 1996-02-20 1997-08-22 Ass Pour Le Dev De La Rech En Recepteur nucleaire de glucocorticoides modifie, fragments d'adn codant pour ledit recepteur et procedes dans lesquels ils sont mis en oeuvre
US6093873A (en) * 1996-08-19 2000-07-25 Institut National De La Sante Et De La Recherche Medicale Genetically engineered mice containing alterations in the gene encoding RXR
US5945577A (en) 1997-01-10 1999-08-31 University Of Massachusetts As Represented By Its Amherst Campus Cloning using donor nuclei from proliferating somatic cells
CA2294916A1 (fr) 1997-07-03 1999-01-14 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth As Represented By Its Amherst Campus Clonage a l'aide de noyaux donneurs a partir de cellules differentiees ne presentant pas de carence serique
SE9703663D0 (sv) * 1997-10-08 1997-10-08 Pharmacia & Upjohn Ab Beta recombinase
JP4206154B2 (ja) * 1997-11-13 2009-01-07 大日本住友製薬株式会社 変異型ｌｏｘＰ配列とその応用
US6331659B1 (en) 1998-01-21 2001-12-18 University Of Hawaii Cumulus cells as nuclear donors
JP2002537311A (ja) 1999-02-19 2002-11-05 オクタジーン・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ホルモン−ホルモン受容体の複合体および核酸構築物、並びに遺伝子治療におけるそれらの使用

Also Published As

Publication number Publication date
DE60134588D1 (de) 2008-08-07
EP1692936B1 (fr) 2008-06-25
US7112715B2 (en) 2006-09-26
US20020100068A1 (en) 2002-07-25
FR2814642A1 (fr) 2002-04-05
ATE398922T1 (de) 2008-07-15
EP1692936A1 (fr) 2006-08-23

Similar Documents

Publication Publication Date Title
FR2814642B1 (fr) Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
Doxiadis et al. Unprecedented polymorphism of Mhc-DRB region configurations in rhesus macaques
ZA99133B (en) Transgenic rabbit that expresses a functional human lipoprotein (A).
ATE301193T1 (de) Modifizierten glucocorticoid rezeptor, fusionsproteinen, und dna sowie diese rezeptorund fusionsproteinen kodierenden
MXPA05014215A (es) Mapeo de genoma de elementos funcionales de adn y proteinas celulares.
DK0798378T3 (da) Estrogen-receptor
ATE535615T1 (de) Chemisch modifizierte nukleinsäuren und methode zur kopplung von nukleinsäuren an einen festen träger
DK1645631T3 (da) Neisseria antigener og præparater
ATE318900T1 (de) Ef-1-alpha transkriptionsregulatorische dna aus hamster
DE60045796D1 (de) Gesamt-chromosom analyse von protein-dns wechselwirkungen
ATE412432T1 (de) Internalisierende erbb2 antikörper
NO995458L (no) Humane 12-lignende reseptorproteiner, beslektede reagenser og metoder
WO2001090340A3 (fr) Ensemble directionnel de grands genomes viraux et de chromosomes
WO2002028175A3 (fr) Sousris transgenique pour recombinaison ciblee a mediation par cre-er modifie
MXPA02008239A (es) Gen humano de la esquizofrenia.
DE69823372D1 (de) Verfahren und reagentiensatz zur amplifizierung, sequenzierung und typisierung von hla i genen
ATE309540T1 (de) Analytisches verfahren unter verwendung von multipelviren-markierung
ATE251886T1 (de) Verwendunf von apoe zum binden von tau und map2c proteinen und zur behandlung von alzheimer's krankheit
ATE319819T1 (de) Humane hirn-spezifische carboxypeptidase b
Heller et al. Ctenosciara alexanderkoenigi sp. n.(Diptera: Sciaridae), an exotic invader in Germany?
DE69835813D1 (de) Verfahren zur kultivierung von zellen und zur vermehrung von viren
DE602004022972D1 (de) Mit cmv-resistenz assoziierter molekularer marker und verwendung davon
IS4957A (is) Hreinsuð prótein, samskeyttar DNA raðir og aðferðir til að stýra þroskun kaffiplantna
DE69737476D1 (de) Neuer galaninrezeptor
DE69811677D1 (de) Verfahren zur präparation von enantiomer-angereicherten, n-derivatisierten laktamen.

Legal Events

Date Code Title Description
TP Transmission of property
TP Transmission of property
ST Notification of lapse

Effective date: 20080630